CClinicalTrials.gg
RecruitingNCT07772869Updated Sep 14, 2026

Uterine Lavage to Detect Ovarian Cancer Risk

An interventional study of Uterine Lavage and Archive Sample in BRCA Hereditary Ovarian Carcinoma, Fallopian Tube High Grade Serous Adenocarcinoma and Ovarian High Grade Serous Adenocarcinoma, sponsored by University of Washington. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by University of Washington · Not applicable, Interventional, and Screening

Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

This clinical trial develops a non-surgical approach using uterine lavage samples to screen for progression to ovarian cancer in high-risk patients carrying BRCA mutations. Women with inherited mutations in the BRCA1 and BRCA2 genes (BRCA carriers) have a much higher lifetime risk of developing ovarian cancer. Currently there are no effective ovarian cancer screening or early detection tests for BRCA carriers. Uterine lavage is a procedure that uses saline to rinse and collect cells from the fallopian tube. Molecular analysis of these samples may help proactively detect genetic alterations that are indicative of progression to ovarian cancer in women with BRCA mutations.

Read the detailed description

OUTLINE:

Patients undergo uterine lavage prior to their standard of care (SOC) risk-reduction surgery and uterine lavage samples undergo molecular analysis on study.

02

Conditions studied

  • BRCA Hereditary Ovarian Carcinoma
  • Fallopian Tube High Grade Serous Adenocarcinoma
  • Ovarian High Grade Serous Adenocarcinoma
  • Primary Peritoneal High Grade Serous Adenocarcinoma
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • > 18 years of age
  • Have a pathogenic BRCA1 or BRCA2 germline variant
  • Planned risk-reduction surgery
  • Presence of uterus and at least one fallopian tube

Exclusion criteria

Exclusion Criteria:

  • Prior tubal ligation
  • Prior history of known ovarian or endometrial cancer
04

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    Screening (uterine lavage)

    Patients undergo uterine lavage prior to their standard of care risk-reduction surgery and uterine lavage samples undergo molecular analysis on study.

    Other: Uterine Lavage · Procedure: Archive Sample · Other: Survey Administration

Interventions

  • OtherUterine Lavage

    Undergo uterine lavage

    Also known as: Irrigation, Wash

  • ProcedureArchive Sample

    Ancillary studies

  • OtherSurvey Administration

    Ancillary studies

05

What researchers measure

Primary outcomes

  1. TP53 mutation burden (MB)

    Will compare TP53 MB in lavages of women with and without serous tubal intraepithelial carcinoma/high grade serous carcinoma (HGSC).

    Time frame: Up to 2 years

  2. Correlation of TP53 mutation burden (MB) in lavages with known HGSC risk factors

    Will correlate TP53 MB in lavages with known HGSC risk factors (age, CA125, parity, age of menarche, and use of oral contraceptives) using univariate and multivariate linear models.

    Time frame: Up to 2 years

  3. Comparison of TP53 mutation burden (MB) in lavages between BRCA carriers with and without multiple TP53 pathogenic clones in fallopian tube tissue

    TP53 MB in lavages will also be compared between BRCA carriers with and without multiple TP53 pathogenic clones in fallopian tube tissue.

    Time frame: Up to 2 years

  4. Correlation of TP53 mutation burden (MB) in fallopian tubes and uterine lavages with the presence and number of cell clusters with positive immunostaining for TP53 in fallopian tubes

    Will assess the correlation of TP53 MB in fallopian tubes and uterine lavages with the presence and number of cell clusters with positive immunostaining for TP53 in fallopian tubes.

    Time frame: Up to 2 years

06

Study locations

1 of 1 sites recruiting
  • Fred Hutch/University of Washington Cancer Consortium
    Seattle, Washington 98109, United States
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07772869
Lead sponsor
University of Washington
Responsible party
Sponsor
First posted
Aug 19, 2026
Start date
Sep 3, 2026
Primary completion
Jun 1, 2028 (estimated)
Completion
Jun 1, 2028 (estimated)
Last update
Sep 14, 2026

Study contacts

Intake Coordinators
Contact
swisherlabrc@uw.edu
206-616-3913
Intake Coordinators
Contact
swisherlabrc@uw.edu
206-616-2532
Barbara Norquist, MD
principal investigator · Fred Hutch/University of Washington Cancer Consortium

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion